Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Groups urge tobacco legislation

This article was originally published in The Tan Sheet

Executive Summary

A report released Feb. 20 by a coalition of public health organizations says that the current lack of government regulation gives the tobacco industry "free reign" to target children, mislead consumers and discourage smokers from quitting. Specifically, the study says flavored products, such as cigarettes flavored like candy, fruit and alcohol "mask the harshness of the products" making them "more appealing to children." In an effort to snuff sales of this "insidious new generation of tobacco products," Sen. Richard Durbin, D-Ill., joined the coalition in issuing the report, promoting legislation that would give FDA authority to regulate tobacco products and their marketing. Durbin introduced S.625 and Rep. Henry Waxman introduced H.R. 1108 early last year to empower FDA to ban candy-flavored cigarettes, require companies to disclose ingredients in tobacco products, require removal of harmful ingredients and prohibit claims such as "reduced risk," "low-tar," "light" and "mild"...

You may also be interested in...



FDA authority over tobacco?

The House Energy and Commerce Committee April 3 approved a bill, H.R. 1108, that would give FDA authority to regulate tobacco, although the legislation would prevent the agency from banning cigarettes altogether or from requiring nicotine-free products. Under the bill introduced by Rep. Henry Waxman, D-Calif., industry user fees would fund FDA's tobacco regulation, including establishing an oversight office. The legislation would allow FDA to monitor cigarette labeling, ban flavored cigarettes and limit advertisements making claims that one product is safer than another (1"The Tan Sheet" Feb. 25, 2008, In Brief)...

BMS, Eisai Team Up To Accelerate Development Of Solid-Tumor ADC

The US firm gets development and co-commercial rights to MORAb-202 for $650m up front. BMS joins AstraZeneca, Merck & Co. and Gilead in recent ADC deal-making.

BIO 2021 Notebook: Best Practices For Business Development

The recently concluded BIO annual meeting included several sessions focused on the practice of business development. In this extra edition of our BIO 2021 notebook, Scrip collected observations about best practices for partnerships.

Topics

UsernamePublicRestriction

Register

PS101394

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel